Immune checkpoint inhibitors (ICI) improve overall survival in patients with metastatic
urothelial cancer (mUC), but therapeutic success at the individual patient level varies …

Background Immune checkpoint blockade (ICB) therapy holds promise in metastatic
urothelial carcinoma (UC). Fibroblast growth factor receptor 3 (FGFR3) mutation drives T-cell …

Antibody-drug conjugates (ADCs) have joined the armamentarium against urothelial cancer
(UC) as an effective therapy option. Since 2019, the US Food and Drug Administration has …

Background The value of programmed cell death ligand-1 (PD-L1) to predict durable
responses to immune checkpoint inhibitors (ICIs) in metastatic urothelial carcinoma (mUC) is …

Precision oncology relies on the accurate molecular characterization of individual patients
with cancer at the time of treatment initiation. However, tumor molecular profiles are not …

High-grade serous ovarian cancer (HGSC), with a modest response to immune checkpoint
blockade (ICB) targeting PD-1/PD-L1 monotherapy, is densely infiltrated by M2-polarized …

Urothelial cancer of the urinary bladder frequently metastasizes to lymph‐nodes, lungs, liver
and bone. A taxonomy for molecular classification exists, but it is unknown if molecular …

Different sources of mutagenesis cause consistently identifiable patterns of mutations and
mutational signatures that mirror the various carcinogenetic processes. We used publicly …

Urothelial cancer (UC) care is moving toward precision oncology. For tumor biology–driven
treatment of metastatic UC (mUC), molecular subtypes play a crucial role. However, it is not …

Alternative therapeutic options targeting urologic malignancies, such as germ cell tumours,
as well as urothelial, renal and prostate carcinomas, are still urgently needed. The …